What's new? Log in Free sign up

Novo Nordisk A/S (NVO)

Company Profile

Company profile

Ticker

NVO, NONOF

Exchange

Website

www.novonordisk.com

CEO

Mr. Lars Fruergaard Jorgensen

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

BEXY COMMUNICATIONS INC, CHENIERE ENERGY INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

NVO stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Annual report of employee stock purchases

Financial summary

Financial statements Chart NVO financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

NVO institutional ownership history Ownership history

9.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1752	1840	-4.8%
Opened positions	149	221	-32.6%
Closed positions	237	109	+117.4%
Increased positions	686	750	-8.5%
Reduced positions	634	574	+10.5%

13F shares	Current	Prev Q	Change
Total value	35.90 tn	43.27 tn	-17.0%
Total shares	333.07 mm	335.52 mm	-0.7%
Total puts	7.78 mm	4.97 mm	+56.3%
Total calls	4.94 mm	5.23 mm	-5.7%
Total put/call ratio	1.6	1.0	+65.7%

Largest owners	Shares	Value	Change
Jennison Associates	20.20 mm	$2.40 tn	-4.8%
FMR	17.93 mm	$2.14 tn	-8.0%
MS Morgan Stanley	14.37 mm	$1.71 tn	-1.7%
BAC Bank of America	14.33 mm	$1.71 tn	+1.0%
Fisher Asset Management	13.31 mm	$1.58 tn	-0.5%
Fayez Sarofim & Co	12.22 mm	$1.45 tn	-2.7%
T. Rowe Price	9.58 mm	$1.14 bn	+0.8%
Folketrygdfondet	8.86 mm	$1.06 tn	+0.3%
Loomis Sayles & Co L P	8.62 mm	$1.03 bn	-3.1%
Renaissance Technologies	8.19 mm	$975.10 bn	-10.6%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	5.51 mm	+5.51 mm	NEW
BLK BlackRock	0.00	-5.46 mm	EXIT
GQG Partners	7.44 mm	+3.22 mm	+76.5%
International Assets Investment Management	1.81 mm	+1.80 mm	+10608.4%
FMR	17.93 mm	-1.56 mm	-8.0%
Millennium Management	709.46 k	-1.46 mm	-67.2%
1832 Asset Management	450.19 k	-1.17 mm	-72.2%
TD Asset Management	0.00	-1.06 mm	EXIT
Jennison Associates	20.20 mm	-1.02 mm	-4.8%
Renaissance Technologies	8.19 mm	-976.06 k	-10.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Novo Nordisk Rises 5% In Premarket As Analyst Dismisses Friday's 17% Plunge As Market Overreaction

Analysts at Intron Health, led by Naresh Chouhan, suggested that Friday's market reaction was excessively severe.

What Analysts Are Saying About Novo Nordisk Stock

BMO Capital Maintains Outperform on Novo Nordisk, Lowers Price Target to $105

BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Outperform and lowers the price target from $156 to $105.

Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?

Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug

Press releases

From Benzinga Pro

Defiance Launches NVOX, the First 2X Leveraged Single-Stock ETF on Novo Nordisk

MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Defiance ETFs today launched NVOX, the world's first single-stock leveraged ETF for the pharmaceutical stock Novo Nordisk (NYSE:NVO). As the weight loss market continues to

BioRestorative Ends Q3 In 'Strong' Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Detroit, Michigan--News Direct--By Meg Flippin, BenzingaBioRestorative Therapies, Inc. (NASDAQ:BRTX), a regenerative medicine company focused on stem cell-based therapies and products, is advancing toward profitability,

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development

Health and Wellness Industry Embraces Surge in Demand for Weight Loss Drugs

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.